/=65 years of
age" [Vaccine 62" />
/=65 years of
age" [Vaccine 62 (2025) 127456].
Vaccine. 2025;64:127688. " />
Read + Share
Kishino H, Inoue S, Matsuoka O, Yagi M, et al. Corrigendum to "A phase 3 randomized trial (STRIDE-9) to evaluate the safety,
tolerability, and immunogenicity of V116, a population-specific pneumococcal
conjugate vaccine, in pneumococcal vaccine-naive Japanese adults >/=65 years of
age" [Vaccine 62 Vaccine 2025;64:127688.
PMID: 40916264
/=65 years of
age" [Vaccine 62&body=Corrigendum to "A phase 3 randomized trial (STRIDE-9) to evaluate the safety,
tolerability, and immunogenicity of V116, a population-specific pneumococcal
conjugate vaccine, in pneumococcal vaccine-naive Japanese adults >/=65 years of
age" [Vaccine 62 Kishino H, Inoue S, Matsuoka O, Yagi M, et al. Vaccine 2025;64:127688. https://m.amedeo.com/40916264 " ALT="Email" TITLE="Email">Email
/=65 years of
age" [Vaccine 62&summary=Kishino H, Inoue S, Matsuoka O, Yagi M, et al. Corrigendum to "A phase 3 randomized trial (STRIDE-9) to evaluate the safety,
tolerability, and immunogenicity of V116, a population-specific pneumococcal
conjugate vaccine, in pneumococcal vaccine-naive Japanese adults >/=65 years of
age" [Vaccine 62 Vaccine 2025;64:127688.&source=https://m.amedeo.com" target="linkedin">LinkedIn
Privacy Policy
